For the quarter ending 2025-09-30, ENTO has $135,370,340 in assets. $45,808,262 in debts. $2,517,218 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 2,517,218 | 4,474 | ||
| Accounts receivable | 37,490 | - | ||
| Prepaid expenses | 451,879 | 144,159 | ||
| Assets of disposal group held-for-sale | 83,170,009 | 83,170,009 | ||
| Other current assets | 1,521,939 | - | ||
| Total current assets | 87,698,535 | 83,318,642 | ||
| Property and equipment, net | 27,520 | - | ||
| Intangible assets, net-Developed Technology Rights | 18,387,000 | - | ||
| Intangible assets, net-Customer Relationships | 2,630,000 | - | ||
| Restricted cash | - | 7,005 | ||
| Intangible assets, net-Trade Names | 782,000 | - | ||
| Goodwill | 25,796,163 | 1,684,182 | ||
| Deposits | 49,122 | 49,122 | ||
| Total other assets | 47,671,805 | 1,740,309 | ||
| Total assets | 135,370,340 | 85,058,951 | ||
| Accounts payable | 4,973,285 | 3,298,447 | ||
| Accrued expenses | 410,324 | 415,444 | ||
| Deferred consideration- short term | 2,000,000 | - | ||
| Accrued dividend payable | 1,564,753 | 1,474,009 | ||
| Line of credit | 700,000 | 700,000 | ||
| Operating lease liabilities - current | 135,609 | 135,609 | ||
| Liabilities held-for-sale | 23,672,708 | 23,546,478 | ||
| Other current liabilities | 59,482 | 105,918 | ||
| Total current liabilities | 33,516,161 | 29,675,905 | ||
| Deferred consideration- long term | 5,000,000 | - | ||
| Due to related party | 7,292,101 | - | ||
| Total stockholders' equity (deficit) | - | -6,298,054 | ||
| Total liabilities | 45,808,262 | 29,675,905 | ||
| Total mezzanine equity-Series GPreferred Stock | 61,681,100 | 61,681,100 | ||
| Preferred stock-Series BPreferred Stock | 0 | 0 | ||
| Preferred stock-Series CPreferred Stock | 0 | 0 | ||
| Preferred stock-Series DPreferred Stock | 0 | 0 | ||
| Preferred stock-Series EPreferred Stock | 0 | 0 | ||
| Preferred stock-Series FPreferred Stock | 0 | 0 | ||
| Preferred stock-Series HPreferred Stock | 4 | - | ||
| Common stock - par value 0.0001 per share 100,000,000 shares authorized 2,547,147 and 1,584,650 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 255 | 477 | ||
| Additional paid-in capital | 228,392,426 | 198,347,367 | ||
| Accumulated deficit | -205,798,707 | -204,645,898 | ||
| Non-controlling interest | 5,287,000 | - | ||
| Total stockholders' equity (deficit) | 27,880,978 | - | ||
| Total liabilities, mezzanine equity and stockholders' equity (deficit) | 135,370,340 | 85,058,951 | ||
Entero Therapeutics, Inc. (ENTO)
Entero Therapeutics, Inc. (ENTO)